ESR1 and breast carcinoma: Studies have shown that the benefits of breast cancer chemotherapy are rarely achieved in the subgroup of patients with “highly endocrine-sensitive” tumors, as defined by more than 50% of cells expressing both ER and PR, based on immunohistochemistry, and insufficient amplification of HER-2 [22].